Abstract
Proliferative vitreoretinopathy (PVR) can occur in eyes with rhegmatogenous retinal detachment (RRD) or after RRD surgery, and it is the most common cause of failure of this surgery, accounting for about 75% of all primary failures. Complex biological pathways induce PVR development, with growth factors and cytokines from the vitreous and from the serum (as a result of the breakdown of the blood-retinal barrier) stimulating RPE and Muller cells transformation and proliferation, and membrane formation and contraction.
Identification of pre-operative risk factors, recognition of the early signs of PVR, use of adequate surgical techniques and of pharmacological therapy can reduce the PRV incidence.
Steroids can influence the inflammatory and proliferative components of PVR, by reducing the breakdown of the blood-retinal barrier, and the proliferation of Müller cell and of RPE cells. Some new formulation of intravitreal steroids are promising tool for the prevention of the PVR formation in eyes treated by vitreoretinal surgery.
Keywords: Intravitreal steroids, prevention, proliferative vitreoretinopathy, retinal detachment.
Current Pharmaceutical Design
Title:Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment
Volume: 21 Issue: 32
Author(s): Caterina Gagliano, Mario D. Toro, Teresio Avitabile, Santo Stella and Maurizio G. Uva
Affiliation:
Keywords: Intravitreal steroids, prevention, proliferative vitreoretinopathy, retinal detachment.
Abstract: Proliferative vitreoretinopathy (PVR) can occur in eyes with rhegmatogenous retinal detachment (RRD) or after RRD surgery, and it is the most common cause of failure of this surgery, accounting for about 75% of all primary failures. Complex biological pathways induce PVR development, with growth factors and cytokines from the vitreous and from the serum (as a result of the breakdown of the blood-retinal barrier) stimulating RPE and Muller cells transformation and proliferation, and membrane formation and contraction.
Identification of pre-operative risk factors, recognition of the early signs of PVR, use of adequate surgical techniques and of pharmacological therapy can reduce the PRV incidence.
Steroids can influence the inflammatory and proliferative components of PVR, by reducing the breakdown of the blood-retinal barrier, and the proliferation of Müller cell and of RPE cells. Some new formulation of intravitreal steroids are promising tool for the prevention of the PVR formation in eyes treated by vitreoretinal surgery.
Export Options
About this article
Cite this article as:
Gagliano Caterina, Toro D. Mario, Avitabile Teresio, Stella Santo and Uva G. Maurizio, Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909100212
DOI https://dx.doi.org/10.2174/1381612821666150909100212 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues
Current Medicinal Chemistry CB-12181, a New Azasugar-Based Matrix Metalloproteinase/Tumor Necrosis Factor-α Converting Enzyme Inhibitor, Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and Retinal Neovascularization in Vivo
Current Neurovascular Research Cerebral Vascular Aging: Extending the Concept of Pulse Wave Encephalopathy Through Capillaries to the Cerebral Veins
Current Aging Science Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Current Molecular Understanding and Future Treatment Strategies for Pathologic Ocular Neovascularization
Current Molecular Medicine The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Subtypes of Antiphospholipid Antibodies in Neurologic Disorders: An Observational Study
Current Rheumatology Reviews Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration
Current Drug Targets Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report
Current Drug Safety Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety Involvement of Orbital Structures in Rheumatic Disease
Current Rheumatology Reviews Adult Stem Cell Therapy for Acute Brain Injury in Children
CNS & Neurological Disorders - Drug Targets